Moreover, the study was conducted in a pre-immunotherapy era, and no treatment-naïve patients were included in this analysis, and molecular profiling of the tumor was not routinely performed at the time, precluding further subgroup analyses on the mutational status of selected genes, such as PIK3CA mutation, PTEN loss, etc. The gene discussed is PIK3CA; the disease is neoplasm.